From the Research
Metformin at a dose of 2 gm Q 12 hrs may be beneficial for treating OA pain in patients with overweight or obesity, as evidenced by a recent randomized clinical trial 1. The use of metformin for osteoarthritis (OA) pain management has been explored in several studies, with varying results. However, the most recent and highest quality study, a randomized clinical trial published in 2025, found that metformin reduced knee pain in patients with symptomatic knee OA and overweight or obesity 1. Key points to consider:
- The study found a significant reduction in knee pain, with a mean change in VAS pain of -31.3 mm in the metformin group compared to -18.9 mm in the placebo group 1.
- The most common adverse events were diarrhea and abdominal discomfort, which were generally mild and self-limiting 1.
- The study suggests that metformin may be a useful treatment option for OA pain in patients with overweight or obesity, particularly those who have not responded to other treatments.
- It is essential to note that metformin is not a traditional pain medication and should not be used as a replacement for established OA pain management strategies, such as acetaminophen, NSAIDs, or physical therapy.
- Further research is needed to confirm the findings of this study and to determine the optimal dosage and duration of metformin treatment for OA pain.